These agents robustly activated STING-mediated antitumor immunity in colorectal cancer models, reversed “cold” tumor phenotypes, and exhibited efficacy in triple-negative breast cancer, with further enhancement upon immune checkpoint inhibitor combination (89). Here, STING1 is linked to triple-negative breast carcinoma.